The value of big data – Part 1: Big board games

I collect board games, and probably, I collect too many of them. Each game is different and has its own charm and value. Some are fun for large groups, others work best when you play them one-on-one. Sometimes what draws me to a game is a great theme and sometimes it’s a novel mechanic. Regardless, there is something about all of them that makes me want them.
Board game and dice
Sadly, I only have so much time in a day and only so much of that can be devoted to playing games. My shelves are getting full with great games that I’ve never played, some even still have the shrink-wrap on them, never opened and likely never will be. To be honest, I have a problem. I have a wealth of entertainment value but no real way to appreciate it. When I buy games, I ignore the fact that I already have 20 games sitting ready to be played that haven’t been touched. And, among those games I have played, rarely have I truly mined their depths, rather I end up playing them once or twice and move on before getting all their worth.

Yes, I have a problem, and I call that problem “Big Board Games.” I have games of great variety and volume, acquired at high velocity and all having (at least to me) great value. All of you reading this probably think what a waste of money my games might be, or, at best what an interesting quirk for a statistician. But if I were to have told the same story in the context of data, we would think of this as a source of universal pride and envy.

It is a rare case that we stumble upon big data by accident or surprise. It is a deliberate process by which we desire and acquire new data sources. Some sources come from changes in technology allowing us to capture more detailed or more frequent data, perhaps a new type of genetic assay. Some sources come from vendors who sell EMR, claims or other rich sources of data. Sometimes we get lucky and find new ways to analyze previously inaccessible data; for instance text mining of EMR notes from a previously purchased source. But all of it we knowingly capture and all of it comes at a cost to us.

Granted, I’m a bit long-winded in getting to the point, but the point is a valid one. The acquisition of big data in and of itself isn’t a point of pride. Rather, the presence of big data indicates a data acquisition strategy that may be out of pace with the corresponding analytic support capability. We will all face times where we step into the realm of big data; this is a necessary product of growth and exploration. But those periods should be short-lived and carefully evaluated. We should be asking ourselves what was the factor that pushed us into a state of big data, and is the corresponding value worth the cost of acquisition – and more importantly, is it worth the cost of utilization?

When I store a new batch of board games on my shelves at home, I find I often have an introspective moment. As I rearrange and push aside old games I’m forced to ask myself whether these new games truly add value to my collection and enjoyment. Through acquisition of games, even great games, my ability to play isn’t increased, yet the potential pool for demand is growing constantly. Some games must be diminished, others forgotten almost completely; and yet, while I’m aware of all of this potential waste and lost value, there’s always one other great game that I just have to get next.

And so it goes with big data, as we’ll see in Part 2 and Part 3 of this series.

Post a Comment

Clinical trial data transparency – making the commitment

A great deal of progress has been made to increase data transparency for clinical trials. The sponsors who have rapidly increased transparency deserve our gratitude. They’re the reason why, now more than ever, more progress is possible through commitments to action on data transparency by all sponsor organizations.

Data transparency gives authorized researchers access to the clinical trial data on which the regulatory decisions for new medicines are based. In late 2013, I wrote about “Five Steps to Success” with clinical trial data transparency. These five steps were:

  1. Decide to participate.
  2. Make the data decisions.
  3. Implement a governance process.
  4. Deploy a secure analytics repository.
  5. Inform the research community and the public.

Considerable progress in a very short time

In a very short timeframe, many biopharmaceutical companies have elected to make clinical trial data and supporting documents available to researchers through various approaches, such as:

  1., which currently provides study information for eight clinical trial sponsors.
  2. University-affiliated “independent review committees.” At least one company is using The Yale School of Medicine’s Open Data Access Project (YODA) to gather and review researcher requests. In addition, Duke Clinical Research Institute (CDRI) is providing an independent review committee to review researcher data access requests for a biopharmaceutical company.
  3. Consortiums such as Project Data Sphere – an initiative of the CEO Roundtable on Cancer’s Life Sciences Consortium.
  4. Pharma company websites. Some organizations are providing the ability to request clinical data access from their own company website.

While the list of organizations that have committed to greater transparency grows with each passing month, some sponsors of clinical trials have not taken action.

Some companies are waiting

Although a great deal of progress has been made in a very short time by the early pioneers of clinical trial data transparency, some biopharmaceutical organizations are waiting to take action toward providing researchers with access to anonymized patient-level data from their clinical trials. Why take a wait-and-see approach? Perhaps these organizations are waiting for a regulatory mandate. Or maybe they hope the stakeholders requesting greater transparency will be satisfied by the current progress.

The bottom line is that the stakeholders demanding greater transparency into clinical trial results expect full participation and not partial transparency.

Commitment requires action

Delaying the decision to participate isn’t a sound strategy, and here’s why:

  • High participation rates from all sponsors can help to prevent further scrutiny from regulatory authorities and other stakeholders.
  • Regulatory mandates may be more onerous if the entire industry is not showing progress by taking immediate action to implement data transparency.
  • The stakeholders are resolute. You can expect the advocates for greater transparency to be extremely dedicated – even tenacious – in pursuing access to clinical study data.

Increased access to clinical trial data for authorized researchers can be a valuable resource for the discovery of new medical knowledge. The new insights will have the potential to improve public health for decades to come. Greater transparency also helps to increase public trust in the industry. Commitment and action from all sponsors of clinical research will help to make data transparency a reality.

To learn more about how SAS can help, visit our clinical data transparency page on

Post a Comment

Visual analytics – A step in the right direction

I just returned from the invigorating Healthcare Analytics Symposium & Expo in Chicago. The event was focused on the analytical competencies needed to navigate the shifting landscape of health care reform, and traverse the gap between FFS (fee for service) and FFV (fee for value). Although only in its third year, I wasn't surprised to see attendance double from last year. The word is out; analytical competency will be critical to everyone’s success in this industry.

Two themes seemed to dominate the Q&A, hallway discussions, and conversations with visitors to the SAS booth: First, the difference between business intelligence (BI) and analytics; and second, the need to predict and manage both clinical and financial risk. This was very encouraging to me, because last year’s themes where very different. Last year, many participants assumed that BI (or "reporting") and analytics were synonymous, and that their most urgent need was to build a clinical data warehouse (CDW) for reporting and scorecards. Fortunately, many have since learned the differences between reporting and predictive modeling and are beginning to warm to the notion that a CDW is not necessarily their best first step on the road to analytical competence.

Necessity is the mother of invention: most health care organizations have lots of data trapped in their EMR, but don't yet have a CDW to extract and organize the data for reporting. As such, almost everyone I spoke with this year was seeking advice and answers to the following two questions:

  1. How can I do basic yet meaningful clinical analytics without a data warehouse? 
  2. How can I do basic, yet meaningful clinical analytics without a staff of bioinformaticians?

The answer to both questions is surprisingly simple – use SAS® Visual Analytics.

A mere two years ago, the answers to both of those questions were far more complex. Now, things are much simpler. SAS Visual Analytics is a powerful, yet intuitive tool for exploring data and building reports – that doesn't require a prebuilt warehouse with cubes and marts. It's so easy to use that it requires no training to get started. Best of all, you don't have to be a biostatistician to perform correlation analysis or create a quick forecast.

This solution represents tremendous opportunity for the use of analytics in health care for several reasons:

  • It reduces the barrier to entry for non-statisticians to engage in analytical decision-making.
  • It dramatically reduces the time-to-value for investment in analytical capabilities.
  • It reduces dependence on already over-burdened HIT organizations.
  • It's a steppingstone toward a more sophisticated level of analytical maturity.
  • It makes analytical insights accessible to clinicians who haven't the time or energy to gather it any other way.

The conference reminded me that many health care organizations are just beginning their journey to analytical competence. An old adage comes to mind, “Think big, start small, and move fast!” SAS Visual Analytics provides the opportunity to do just that; don't wait on that warehouse ... get started now. Go online and give it a try.

Post a Comment

Prescription for analytics: Ten smart moves to develop your strategy and culture

The health care industry has only scratched the surface of what big data analytics can do to advance the triple aim. It’s an open secret that if health and life science companies could analyze the big health data they already have – even before bringing in novel data sources – they could gain unprecedented insight to make enormous improvements in health care delivery, costs and outcomes.

However, much of this opportunity is untapped – not due to technologic or even data constraints, but cultural ones. I see it every day in my work as part of SAS Best Practices. Changing the culture is about adapting mindsets and business processes – creating an environment where people understand, value and demand fact-based decisions and strategies.

At the 11th annual SAS Health Analytics Executive Conference last week, I spoke with experts who shared what’s worked for them as they developed an analytic culture in their organizations. I’ve boiled this valuable information down to ten smart approaches for transforming from within:

  1. Think big, start small and move fast.
    It’s great to have a vision, a strategy and a dream of where you want to get to, but start small and move fast with getting those things done. Too broad a vision and you’ll never get off the ground. And because breaking new ground is inherently risky, it’s important to not only move fast but to fail fast and move on quickly if a particular analytic experiment comes up empty.
  2. Don’t baffle them with equations.
    Most people have a lingering math phobia from school days. They see a statistician coming  and fear you’re going to smother them with equations. Tell stories and provide relatable analogies, and people don’t have to be afraid.
  3. Present a business case, not an analytics case.
    The quants amongst us think the beauty of analytics should be self-evident. Even so, you have to present your case in business terms, with a plan to deliver quantifiable costs and benefits. This makes it hard for that C-(Anything)-O to say no.
  4. Show them you’re really going to help them.
    Understand – and communicate to your consumers - that an analytics project is not about generating another report. Rather, the objective is to integrate new insights into business processes and practices to help the folks on the ground do what they need – and want – to do more efficiently and effectively.
  5. Show tangible results in their terms.
    Show how you saved money, avoided an erroneous conclusion or suboptimal decision, improved the ability to respond to a patient’s needs, positively impacted outcomes or made a better drug development determination earlier in the process. When you can do that, you gain credibility. Push turns to pull.
  6. Get people to believe in models.
    Yes, scientists and medical professionals are analytical by nature. This doesn’t mean, however, they naturally gravitate to or embrace analytics. Sometimes you have to convince them that models really can represent complex systems. Not sure how?  See #s 2, 4 and 5.
  7. Enable capabilities, not applications
    When you build a broad capability for analytic discovery – the best performance envelope you can – people will surprise you with the innovations they can bring to the table. To commandeer an old saying: teach them to fish. Provide the pole. And perhaps even an initial pond. With some coaching, they’ll take it from there.
  8. Show them the possibilities.
    Business users don’t know what the math can do, so they’re not going to ask you for it. Data scientists might have to be the ones saying, “Here’s something really valuable we can do for you.” Then their eyes start to light up. But remember, action trumps interesting. Make sure you’re speaking to real-world problems and opportunities that matter to them. Not just to you.
  9. Consider an analytics center of excellence (COE).
    Most organizations have pockets of analytics expertise, but you gain great synergies and economies of scale by bringing your brightest stars together to focus on the most important analytical approaches. A center of excellence mobilizes analytic resources for the good of the enterprise – not just for specific business units or one-off projects. Used correctly a COE can play a critical role in transforming your organizational culture to one that embraces the value of analytics-driven decisions.
  10. Make it irresistibly sexy
    If you’ve laid the groundwork – such as building an advanced analytics laboratory – show it off! Invite folks in and experiment together. Share the technology in a very visual way. People will see that when they ask what-if questions, they can get answers instantly. That’s exciting, and inspires everyone to keep asking more questions.

If you missed our Virtual Conference, I invite you to watch the session, An Analytic Prescription: Developing a Robust Strategy and Culture, as well as several others available on-demand.

Post a Comment

Caution: Don’t underestimate the promise of analytics

Big data analytics have ushered in the potential to dramatically improve health care costs, the care experience and patient outcomes. Masses of genomic data, clinical trial data, electronic health records (EHRs), claims data and research study data can be brought together to reveal important discoveries, support better operational and medical decisions  and, ideally, to bring analytic insight right to the point of care.

As Director of Business Strategies for SAS Best Practices, I’ve seen a lot of change in the last 15 years in both the awareness of and execution of analytics programs to drive value. At the 11th annual SAS Health Analytics Executive Conference, I had the privilege of talking with some folks who are leading the analytics charge in pharmaceutical development and integrated health care delivery. In a panel discussion, they described some cases where their organizations are applying analytics to improve quality, close care gaps and accelerate scientific discovery.

  • Quality. Preventable medical errors are a leading cause of death in the US – higher than diabetes. Imagine the opportunity to use data and analytics to reduce such events. Analysis of EHRs can be used to automatically detect misdiagnoses, monitor medication use and better assess risks to provide the optimal therapeutic interventions.
  • Completeness of care. The health care industry lags financial services and retail in the ability create a 360-degree view of the customer/patient/member and deliver the right insights at the right moment. Imagine the potential to deliver analytic results into the exam room while the provider is with the patient, making care decisions. The potential exists to customize not only what, but how, information is communicated to a patient and adjust therapeutic approaches throughout the continuum of care based on a comprehensive understanding of not only a person’s medical history, but their personal preferences, family history and demonstrated behaviors (just to name a few).
  • Speed of scientific discovery.  Did you know that it takes 12 to 14 years and at least $1 billion to develop a drug? A staggering fact shared by one of our conference executives from a leading pharmaceutical company. But analytics can change that. Life sciences organizations are using analytics to design better clinical development programs that identify effective drugs more quickly, and also to identify subgroups of patients for whom a therapy will work particularly well.
  • Real-world understanding. Pharmaceutical companies are working to integrate clinical trial data with real-world evidence. The scientific mandate: we need to do the correct science to create the correct drugs. But there’s also the practical mandate: how are we positively affecting or changing people’s lives?

The bottom line

Those in the health and life sciences professions have a mission to help those they serve. But whether your organization is categorized as for-profit or not-for-profit, if your bottom line isn’t black, you’re not going to be around to help anyone. Analytics can be used to identify waste and inefficiency as well as to optimize the allocation of limited resources – skilled providers, capital, facilities, etc. Smart, lean operational decisions become ever-more critical as we work to transform the health care system from a fee-for-service model to value-based care.

It’s easy to get people to agree in concept about the value of analytics, but it’s not always easy to move from vision to action, from high-level roadmap to implementation. In my next posting I’ll talk about why the industry isn’t exploiting analytics to the degree that it can – and should. Since I work at SAS, I can assure you it’s not a lack of data or analytical horsepower.

If you missed our Virtual Conference, I invite you to watch the session, An Analytic Prescription: Developing a Robust Strategy and Culture, as well as several others available on-demand.

Post a Comment

ANALYTICS power life sciences organizations

My favorite sessions at the SAS Health Analytics Executive Conference are the ones where life science customers describe case studies about the value of analytics in their organization. This year’s conference featured outstanding presentations from Xiaoying Wu, MD of Janssen; Alay Shah of Cardinal Health; and Craig Willis of Physicians Pharmacy Alliance.

Data-driven adaptive clinical trial design

Dr. Xiaoying Wu described a major project at Janssen Research and Development building a data warehouse to support modelling and simulation and clinical trial protocol design. The project supports adaptive clinical trial design and increases the capability for data-driven decision making in the organization.

Before building the data warehouse, it used to take 2 to 14 weeks just to identify the data necessary to answer a question, such as “What is the response rate in placebo arm for disease X?” The tasks would include items such as:

  • Identifying all trials for disease X
  • Locating key documents
  • Locating available data and securing access to the data
  • Understanding previous analyses, and
  • Identifying the right population – among others.

Janssen R&D is now able to more rapidly provide insights for adaptive trial design which will ultimately reduce the cost of clinical trials and shorten time to market – while better meeting the needs of the patient. The project was successful thanks to excellent collaboration between business and IT.

GRID unites silos

A second case study of great collaboration between IT and business users was presented by Alay Shah from Cardinal Health.

The grid implementation at Cardinal Health brought together multiple groups across the organization to use the same platform. Their grid now supports about 800 users, and the excellent support from IT now allows SAS programmers to spend more of their time solving business problems.

As a result of the grid implementation, Cardinal Health was able to eliminate silos, reduce annual server repair and maintenance costs, improve server utilization and improve availability for the SAS platform. In addition, programs now run faster. For example, the runtime for price audits was reduced from 3 hours to 30 minutes!

Alay noted that the most important achievement from this project was to improve the relationship between the SAS users in the business and the internal IT services group.

Transforming their business with analytics

Craig Willis from Physicians Pharmacy Alliance told the captivating story of how his fast growing company is transforming their business with analytics, especially SAS® Visual Analytics and SAS® Office Analytics. Physicians Pharmacy Alliance is a leading medication care management pharmacy that improves adherence and lowers the cost of health care for complex patients.

Physicians Pharmacy Alliance works with managed Medicaid plans to develop a series of analytic algorithms to identify complex patients who are likely to have challenges adhering to their medical regimen. The company needed to find a more scalable way to grow their business than their existing tools provided.

Physicians Pharmacy Alliance has used analytics to transform their business through:

  • Comprehensive claims analysis to drive efficient patient identification
  • Integration of multiple data sources to draw a clear link between adherence and reduced medical spend
  • Automated contractual reporting for their customers.

Learn more

Find out more about Health Analytics by viewing the OnDemand version of the 2014 SAS Health Analytics Conference.

Post a Comment

Five pearls of wisdom from health analytics executive panel

At the 2014 SAS Health Analytics Executive Conference last week, I had the privilege of hosting a panel discussion with three industry leaders representing a cross-section of large, pioneering health and life sciences organizations who are each on the leading edge in their use of analytics to pave the path toward value-based and patient-centered care. The panelists joining me were:

  • Terhilda Garrido, Vice President of Health IT Transformation and Analytics with Kaiser Permanente
  • Patrick McIntyre, Senior Vice President of Health Care Analytics, Wellpoint, and
  • Sai Venkat, Senior Director of Enterprise Architecture for Janssen Pharmaceuticals, Johnson & Johnson.
Executive Leadership panelists at the SAS Health Analytics Executive Conference.

Executive Leadership panelists at the SAS Health Analytics Executive Conference.

Several themes emerged from the discussion; in particular, five are in my opinion especially valuable for others embarking on the same journey towards analytic maturity:

  1. Put the patient at the center. Given that face-to-face health care delivery represents a fraction of the opportunity for improving health and wellness, we need to start thinking about how to establish an “always on” health care system – one that provides individuals with convenient access to a seamless blend of online and face-to-face care services – in the same way that they expect from any other consumer-centric organization. Start to think beyond the static patient portal as the only way to extend interaction beyond the walls of your organization, and think about how to create mass personalization by using data to understand patients as unique individuals.
  2. Collaborate. We heard that there is a growing realization that collaborations are required to gather a truly comprehensive understanding of individual patients as well as populations of patients. Providers, health plans and big pharma have started to form strategic alliances that, over time, can contribute to development of a 360-degree view of the patient; something that would be impossible for any single organization to develop in isolation. This holds the promise of:
    • More rapid and targeted drug development
    • Greater ability to predict which patients are at higher risk and could benefit from earlier intervention
    • Development of win-win risk sharing arrangements
    • Control of spiraling health care costs.
  3. Cross-pollinate. The panelists agreed that too often there are multiple groups within their organizations, each tackling the same types of analytic challenges. Each organization is focused on pooling expertise or sharing best practices to their analytic approaches and insights across the enterprise. For some this means developing a formal Center of Excellence (COE), for others it means establishing routine mechanisms for analytic teams to collaborate across traditional departmental boundaries. Whichever approach is taken, each panelist agreed that they are focused on ensuring that IT, analytics and business leadership are staying in tight lock-step to ensure data-driven initiatives deliver maximum business benefit.
  4. Bring in novel data sources. Our panelists talked about the opportunities associated with bringing EMR and claims data together to build a broad and deep view of the patient. They also described initiatives underway for enriching existing data with novel big data sources. All organizations should consider the potential value of leveraging socioeconomic, consumer, geographic and social media data, while also keeping an eye on a wave of data emerging from mobile apps, wearable devices and other sensor technology. While blending data in this way requires careful attention to ensure that patient privacy is protected, the panel agreed that they are each considering how to leverage this wave of health care big data to improve the health and quality of care for their patients.
  5. Think business, not analytics. The most sophisticated analytics endeavors won’t make a difference if they don’t change or improve something in the real world. Make sure the analytics you conduct is prioritized carefully, aligns with key business strategies and has a clear mechanism to effect change, rather than simply delivering reports or risk scores. While this sounds a bit like motherhood and apple pie, we’re all familiar with cases where increasingly scarce analytic talent isn’t used as effectively as possible or is working in a reactive mode rather that in a proactive, strategic fashion. Analytic maturity means being joined at the hip with the front-line needs of the business.

What will separate the leaders in the changing health care landscape?

As health care continues to evolve, two things are certain: first, consumerism is here to stay and the old adage that the customer is king will rock today’s health care industry. And second, the value-based health care train has left the station and there is no turning back.

Organizations that embrace data to excel in customer experience while being able to measurably move the needle on the cost/quality equation will likely be around in 2020. Those that don’t probably won’t be.

If you missed our Virtual Conference, I invite you to watch the Executive Leadership Panel, as well as several others available on-demand.

Post a Comment

How analytics informs the new health care ecosystem

This week, we had the opportunity to hear from industry leaders at the SAS HLS Virtual conference, where we learned how #HealthAnalytics can inform the future of the health and life sciences industries.

We were fortunate to have John Balla, a SAS expert in customer intelligence, join us for the conference. John has experience with everything from start-ups to Fortune 100 global operators, but he isn’t an industry insider. So as someone who probably knows a little more than the average consumer about the use of analytics, he brings a unique perspective to putting the customer at the center. John’s written an overview of the day in which he considers what the big themes discussed mean to consumers. In his blog post, he addresses four major topics:

Big changes

The three greatest drivers of change in the healthcare ecosystem right now are:

  • Technology and innovation
  • Government mandates
  • Empowered consumers

How Health Analytics moves the needle

Moving the needle  comes from the power of forward-looking predictive analytics, which can change the game for the industry (and the patient).

Health analytics is the treatment plan

Dr. Mostashari summed up the problem: health care “costs too damn much and we’re not getting enough value for it.” But analytics isn't only about controlling costs, it's about getting more value for individual patients.

Caring for the patient as a consumer

Ultimately, health analytics can both support the individual’s ability to make choices about their care more easily - as well as help to drive better outcomes.

I’ve only scratched the surface in this summary; I encourage you to read John’s post in its entirety.


Post a Comment

Health care transformation and the power of prediction

Dr. Farzad Mostashari, a SAS user for 25 years, kicked off the 11th annual SAS Health Analytics Executive Conference yesterday, and made some bold statements regarding transformation and analytics in health care.

“Transformation faces resistance,” he said, and it’s constantly faced with the ‘we’ve been doing it this way for a long time’ mentality. With the change from volume to value, providers and payers alike are frustrated as outcomes and incomes are becoming interrelated. But Mostashari says frustration is in fact a good thing.  Here’s why.

The changing landscape to value-based care is creating a playing field for disruption across the entire ecosystem of health care. And all of these changes are being driven by one thing: cost. We’ve heard it time and time again that we simply cannot continue to spend the growing amount of money each year on health care that we do.  Federal governments, state governments, employers and employees just can’t afford it.

So, Mostashari posed a critical question: What’s going to happen when that cost is revenue? Everyone’s thinking about “who’s going to win,” and as innovators commonly quote, “it’s not disruption unless someone loses their job.” Mostashari questioned the audience of health care leaders - “Are we going to see companies go out of business? Will it be you? What are you going to do? He encouraged these leaders to embrace disruption so that “you’re not one of those.”

Additionally, Mostashari enlightened the room with his discussion on reactive versus proactive analytics, and provided several examples to drive home the criticality of the latter.  Most of us, for example, know about the failures of managed care from the 80s and 90s, and because of this, some of us are skeptics about the current reform. But, what’s different this time around? We have tools now we could only dream of before, Mostashari confidently pointed out.  We can now predict.

We can predict ER visits, predict who will get sick and when, predict outbreaks across communities, and so much more. He highlighted that when people talk about population health, it’s usually a “bunch of reports,” without any insights or action; no insights on how it’s actually going to change anything. He emphasized using the power of prediction and putting yourself on the line.  Moreover, he compared the use of predictive analytics by the Obama 2012 campaign to health care, saying that in health care, every day is “model validation day” – aka election day. Every day someone gets sick, someone is diagnosed with cancer, someone has a heart attack; we have to put ourselves on the line and use prediction to optimize health care.  Every other part of the economy does, and it’s long overdue for health care to get on board.

Post a Comment

#HealthAnalytics virtual conference coming soon to your screen

Anticipation is building for our 2014 Health and Life Sciences Virtual Conference to take place next Wednesday, May 14th, and we’d like to extend the invitation to you.  We’ve got a great lineup of speakers that promise to get into the big issues facing health care and life sciences today, including how health analytics can be applied to solve them.  And it can all be seen on that screen right in front of you.

The star power starts first thing in the morning. Our first keynote will be delivered by Farzad Mostashari, MD (@Farzad_MD), the visionary former National Coordinator for Health Information Technology and current Visiting Fellow at The Brookings Institution.  Of course most of us know Dr. Mostashari as an advocate for electronic medical records.  In his keynote, we anticipate that he'll explore why “data is oxygen for innovation,” and how data from EMRs are creating an ecosystem of applications and services with the promise of solving some of our most pressing health care problems.  This is a talk not to be missed, and a great way to kick off the conference!

If history is a guide, one of the most interesting sessions will be when different industry representatives participate in a panel on the main stage.  Invariably, we find commonalities in the analytics challenges across payer, provider and life sciences industries.  Moderated by our own CMO, Dr. Graham Hughes (@GrahamHughesMD), you’ll hear from executives from Johnson & Johnson, Kaiser Permanente, WellPoint and McKinsey who have succeeded with analytics. This is a great chance to learn what works, and what their vision is for analytics in their organizations.

We’ll have a number of sessions in the afternoon to choose from that cover topics such as data transparency, consumer engagement, and a session on developing an analytics strategy and culture.

You’ll want to make sure you stay with us through the afternoon for our second keynote, as you’ll get to hear from John F. Crowley, Chairman and CEO of Amicus Therapeutics, and the inspiration for the major motion picture Extraordinary Measures. Crowley has a unique perspective as CEO of a 100-person publicly held biopharmaceutical company working on the development of drugs to treat a range of human genetic diseases. His involvement in the biotech industry goes back over a decade and stems from the 1998 diagnosis of his two youngest children, Megan and Patrick, with Pompe disease, a rare and fatal neuromuscular disorder. Crowley embarked on his journey as an entrepreneur to find a treatment that would save his kids' lives – and the lives of thousands of others.

Please join us on Wednesday May 14, 2014 – complimentary registration can be found here And please be sure to participate with us on social media by following @SASAnalytics and using  #healthanalytics.

Post a Comment
  • About this blog

    Welcome to the SAS Health and Life Sciences blog. We explore how the health care ecosystem – providers, payers, pharmaceutical firms, regulators and consumers – can collaboratively use information and analytics to transform health quality, cost and outcomes.
  • Subscribe to this blog

    Enter your email address:

    Other subscription options

  • Archives